Navigation Links
Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis

An international study using ultrasound technology has found that the most potent cholesterol-lowering drug is also effective at halting// early changes in the blood vessels that can lead to atherosclerosis.

“Rosuvastatin arrested the progression of thickened carotid arteries compared to a placebo,” said John R.Crouse, M.D., lead researcher and a professor of endocrinology at Wake Forest University School of Medicine. “The findings show that the benefits of cholesterol management on arteries can be extended to low-risk patients.”

Results from the study were reported today at the annual meeting of the American College of Cardiology in New Orleans and will appear in the March 28 issue of the Journal of the American Medical Association. The research involved people with moderately elevated cholesterol levels who didn’t qualify for treatment under national guidelines.

Participants all had minimal thickening of their carotid arteries, which supply blood to the brain, and were considered at low risk for having a heart attack or dying from a heart-related event based on their age and other risk factors.

Over a two-year period, the therapy lowered low-density lipoprotein, or “bad” cholesterol, by 49 percent and increased high density lipoprotein, or “good” cholesterol, by 8 percent. Triglycerides were reduced by 16 percent and the progression of artery thickness was halted.

Rosuvastatin (sold under the trade name Crestor) is the newest member of a family of drugs known as statins that work to lower levels of cholesterol and other fats in the blood. Other statins have been tested – with similar results – in patients who’ve already had a heart attack or who had high cholesterol levels. This was the first study to evaluate Crestor in a group of people at low risk for heart attacks.

“Atherosclerosis is often advanced before symptoms appear and it hasn’t been clear whether treatment of low-risk individuals is beneficial,” said Crouse. “This study shows that aggressive cholesterol management arrests the progress of even small changes in the arteries.”

The study used ultrasound to assess whether Crestor was effective at halting progressive thickening of the carotid arteries. Vessel thickening is an early sign of atherosclerosis, the deposit of fatty material in blood vessels that can lead to heart attacks and strokes.

There were 984 study participants: 702 were randomly assigned to receive 40 mg of Crestor daily and 282 were randomly assigned to receive a placebo, or inactive tablet. Male participants were between 45 and 70 years old and females were between 55 and 70.

Crestor arrested the development of artery thickening overall and in all 12 sites of the carotid artery that were measured. Drug safety was assessed by vital signs, adverse events, laboratory tests and electrocardiograms. The frequency of adverse events was similar between the two groups and included muscle pain and gastrointestinal disorders.

“The drug was well tolerated during the two-year period and showed a similar safety profile to the placebo,” said Crouse.

The study included 61 primary care practices in the United States and Europe and was conducted between August 2002 and May 2006. Each participant was followed for two years and received an ultrasound exam at the beginning and end of the study and every six months during the study period.

Participants were considered at low risk of a heart attack or death from a heart-related-event based on a formula developed by the National Cholesterol Education Program from the long-running Framingham Heart Study, which takes such factors as age, sex, blood pressure and cholesterol levels into account. Low risk was considered a heart disease risk of less than 10 percent over a 10-year period.

Soure-Newswise
SRM
'"/>




Related medicine news :

1. Cholesterol-lowering therapy benefits older people also
2. Cholesterol-lowering drug Found To greatly Reduce the risk of stroke and heart attack
3. Growing Popularity of Cholesterol-lowering Drugs Raises Concern
4. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
5. Inhaled Steroids Safe & Effective for Children with Asthma
6. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
7. Fluoride Found Effective in Osteoporosis
8. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
9. Implantable Contact Lens Found Safe and Effective
10. Effective And Economical Agent For Anthrax
11. Stem Cell Transplants May Be Effective For MS Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Global Healthcare ... scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare ... activity. The fun run is geared towards children of all ages; it is ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor ... on sciatica in a new episode of "Success Files," which is an award-winning ... innovation and investigates each subject in-depth with passion and integrity. , Sciatica occurs ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... WILMINGTON, Del. (PRWEB) , ... October 12, 2017 ... ... technology and advisory services for healthcare compliance program management, will showcase a range ... and National Association for Assisted Living (NCAL) Convention and Expo to be held ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017 AVACEN Medical , Inc. (AVACEN) announced ... 2017 New Product Innovation Award for Its fibromyalgia pain ... secondary medical device market research by Frost & Sullivan,s industry ... drug-free pain relief product, the AVACEN 100, offers a safe ... widespread pain. ...
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/11/2017)... Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an update ... Puerto Rico , where the company manufactures ... Following a comprehensive onsite assessment, the ... temporary loss of power and minimal water damage due ... have resumed, and the company expects to return to ...
Breaking Medicine Technology: